Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2026-04-04 Regulatory Filings
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (242 characters) and contains only digital signature information without any substantive content or financial data. There is no indication of a report, announcement, or detailed filing. Given the lack of content and the presence of digital signatures only, this document does not fit into any specific report category and is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings.
2026-04-04 English
Trading Window
Regulatory Filings Classification · 100% confidence The document text is extremely short (66 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category for miscellaneous filings or certifications.
2026-03-25 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (66 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. According to the rules, such minimal content without report details or announcements falls under Regulatory Filings (RNS) as a fallback category.
2026-03-10 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (66 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. According to the rules, such a document is best classified as a Regulatory Filing (RNS) as a fallback category for minimal or miscellaneous filings without specific content.
2026-03-02 English
Copy of Newspaper Publication
Regulatory Filings Classification · 85% confidence The document is a stock exchange announcement under Regulation 30 (LODR) enclosing a newspaper clipping of unaudited financial results for the quarter and nine months ended 31.12.2025. It does not contain the full interim report itself but is a regulatory disclosure of publication. This fits the general “Regulatory Filings” category rather than an interim (IR) or earnings release (ER).
2026-01-31 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 92% confidence The document is a lengthy filing (approx. 40,889 characters) submitted to the National Stock Exchange of India and BSE, titled “Outcome of Board Meeting dated 29th January 2026.” It encloses the company’s Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025, together with an Independent Auditor’s Limited Review Report under SEBI Regulation 33. The filing contains full interim financial statements and auditor’s review for a period shorter than a fiscal year, rather than merely announcing that a report is available. This aligns with the definition of an Interim/Quarterly Report (Code: IR). 9M 2026
2026-01-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.